Literature DB >> 31375573

Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Felix Broecker1, Allen Zheng1, Nungruthai Suntronwong2, Weina Sun1, Mark J Bailey1, Florian Krammer1, Peter Palese3,4.   

Abstract

Influenza viruses express two surface glycoproteins, the hemagglutinin (HA) and the neuraminidase (NA). Anti-NA antibodies protect from lethal influenza virus challenge in the mouse model and correlate inversely with virus shedding and symptoms in humans. Consequently, the NA is a promising target for influenza virus vaccine design. Current seasonal vaccines, however, poorly induce anti-NA antibodies, partly because of the immunodominance of the HA over the NA when the two glycoproteins are closely associated. To address this issue, here we investigated whether extending the stalk domain of the NA could render it more immunogenic on virus particles. Two recombinant influenza viruses based on the H1N1 strain A/Puerto Rico/8/1934 (PR8) were rescued with NA stalk domains extended by 15 or 30 amino acids. Formalin-inactivated viruses expressing wild-type NA or the stalk-extended NA variants were used to vaccinate mice. The virus with the 30-amino-acid stalk extension induced significantly higher anti-NA IgG responses (characterized by increased in vitro antibody-dependent cellular cytotoxicity [ADCC] activity) than the wild-type PR8 virus, while anti-HA IgG levels were unaffected. Similarly, extending the stalk domain of the NA of a recent H3N2 virus enhanced the induction of anti-NA IgGs in mice. On the basis of these results, we hypothesize that the subdominance of the NA can be modulated if the protein is modified such that its height surpasses that of the HA on the viral membrane. Extending the stalk domain of NA may help to enhance its immunogenicity in influenza virus vaccines without compromising antibody responses to HA.IMPORTANCE The efficacy of influenza virus vaccines could be improved by enhancing the immunogenicity of the NA protein. One of the reasons for its poor immunogenicity is the immunodominance of the HA over the NA in many seasonal influenza virus vaccines. Here we demonstrate that, in the mouse model, extending the stalk domain of the NA protein can enhance its immunogenicity on virus particles and overcome the immunodominance of the HA without affecting antibody responses to the HA. The antibody repertoire is broadened by the extended NA and includes additional ADCC-active antibodies. Our findings may assist in the efforts toward more effective influenza virus vaccines.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  immunodominance; influenza virus; neuraminidase; vaccine

Mesh:

Substances:

Year:  2019        PMID: 31375573      PMCID: PMC6714795          DOI: 10.1128/JVI.00840-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses.

Authors:  Matthew R Sandbulte; Kim B Westgeest; Jin Gao; Xiyan Xu; Alexander I Klimov; Colin A Russell; David F Burke; Derek J Smith; Ron A M Fouchier; Maryna C Eichelberger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  The structure and receptor binding properties of the 1918 influenza hemagglutinin.

Authors:  S J Gamblin; L F Haire; R J Russell; D J Stevens; B Xiao; Y Ha; N Vasisht; D A Steinhauer; R S Daniels; A Elliot; D C Wiley; J J Skehel
Journal:  Science       Date:  2004-02-05       Impact factor: 47.728

3.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

4.  Clustal W and Clustal X version 2.0.

Authors:  M A Larkin; G Blackshields; N P Brown; R Chenna; P A McGettigan; H McWilliam; F Valentin; I M Wallace; A Wilm; R Lopez; J D Thompson; T J Gibson; D G Higgins
Journal:  Bioinformatics       Date:  2007-09-10       Impact factor: 6.937

Review 5.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

6.  Influenza virus pleiomorphy characterized by cryoelectron tomography.

Authors:  Audray Harris; Giovanni Cardone; Dennis C Winkler; J Bernard Heymann; Matthew Brecher; Judith M White; Alasdair C Steven
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-04       Impact factor: 11.205

7.  Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.

Authors:  Taia T Wang; Gene S Tan; Rong Hai; Natalie Pica; Erin Petersen; Thomas M Moran; Peter Palese
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

8.  Emergence and genetic variation of neuraminidase stalk deletions in avian influenza viruses.

Authors:  Jinling Li; Heinrich Zu Dohna; Carol J Cardona; Joy Miller; Tim E Carpenter
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

9.  Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.

Authors:  Christopher J Vavricka; Qing Li; Yan Wu; Jianxun Qi; Mingyang Wang; Yue Liu; Feng Gao; Jun Liu; Enguang Feng; Jianhua He; Jinfang Wang; Hong Liu; Hualiang Jiang; George F Gao
Journal:  PLoS Pathog       Date:  2011-10-20       Impact factor: 6.823

10.  Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

Authors:  Matthew R Sandbulte; Gretchen S Jimenez; Adrianus C M Boon; Larry R Smith; John J Treanor; Richard J Webby
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

View more
  9 in total

1.  The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.

Authors:  Atsushi Kawai; Yasuyuki Yamamoto; Takuto Nogimori; Kohei Takeshita; Takuya Yamamoto; Yasuo Yoshioka
Journal:  J Virol       Date:  2021-08-11       Impact factor: 5.103

2.  Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.

Authors:  Zach Menne; Vasilis C Pliasas; Richard W Compans; Sheniqua Glover; Constantinos S Kyriakis; Ioanna Skountzou
Journal:  Virology       Date:  2021-08-05       Impact factor: 3.513

3.  Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals.

Authors:  Allen Zheng; Weina Sun; Xiaoli Xiong; Alec W Freyn; Julia Peukes; Shirin Strohmeier; Raffael Nachbagauer; John A G Briggs; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

Review 4.  Host immune response-inspired development of the influenza vaccine.

Authors:  Angela Choi; Adolfo García-Sastre; Michael Schotsaert
Journal:  Ann Allergy Asthma Immunol       Date:  2020-04-20       Impact factor: 6.347

Review 5.  Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.

Authors:  Sarah Creytens; Mirte N Pascha; Marlies Ballegeer; Xavier Saelens; Cornelis A M de Haan
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

6.  Structure-based design of stabilized recombinant influenza neuraminidase tetramers.

Authors:  Daniel Ellis; Julia Lederhofer; Oliver J Acton; Yaroslav Tsybovsky; Sally Kephart; Christina Yap; Rebecca A Gillespie; Adrian Creanga; Audrey Olshefsky; Tyler Stephens; Deleah Pettie; Michael Murphy; Claire Sydeman; Maggie Ahlrichs; Sidney Chan; Andrew J Borst; Young-Jun Park; Kelly K Lee; Barney S Graham; David Veesler; Neil P King; Masaru Kanekiyo
Journal:  Nat Commun       Date:  2022-04-05       Impact factor: 17.694

7.  A Novel Neuraminidase Virus-Like Particle Vaccine Offers Protection Against Heterologous H3N2 Influenza Virus Infection in the Porcine Model.

Authors:  Vasilis C Pliasas; Zach Menne; Virginia Aida; Ji-Hang Yin; Maria C Naskou; Peter J Neasham; J Fletcher North; Dylan Wilson; Katharine A Horzmann; Joshy Jacob; Ioanna Skountzou; Constantinos S Kyriakis
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

8.  Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.

Authors:  Amanda L Skarlupka; Anne-Gaelle Bebin-Blackwell; Spencer F Sumner; Ted M Ross
Journal:  J Virol       Date:  2021-08-10       Impact factor: 5.103

9.  Site-Specific Glycan-Masking/Unmasking Hemagglutinin Antigen Design to Elicit Broadly Neutralizing and Stem-Binding Antibodies Against Highly Pathogenic Avian Influenza H5N1 Virus Infections.

Authors:  Ting-Hsuan Chen; Ya-Lin Yang; Jia-Tsrong Jan; Chung-Chu Chen; Suh-Chin Wu
Journal:  Front Immunol       Date:  2021-07-14       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.